



Corrigendum

Corrigendum to “Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine”

[*J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* 893–894 (2012) 92–100]



A.C. Dubbelman ^{a,b,*}, M. Tibben ^b, H. Rosing ^b, A. Gebretensae ^b, L. Nan ^b, S.H. Gorman ^c, P. Robertson Jr. ^c, J.H.M. Schellens ^{a,d}, J.H. Beijnen ^{b,d}

^a Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands

^b Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands

^c Department of Global Nonclinical DMPK, Teva Pharmaceutical Industries Ltd., 145 Brandywine Parkway, West Chester, PA 19380, United States

^d Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584CA Utrecht, The Netherlands






An error in **Table 2** concerning the structure of bendamustine and its metabolites M3, M4 and HP2 and the internal standard BM-IS has now been corrected, by placing the bis(2-chloroethyl)amino group (or its hydrolysed derivative in case of HP2) at the 5-position of the benzimidazole moiety.

DOI of original article: <http://dx.doi.org/10.1016/j.jchromb.2012.02.039>.

* Corresponding author at: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
E-mail address: a.c.dubbelman@lacdr.leidenuniv.nl (A.C. Dubbelman).

Table 2

Analytes with their selected mass transitions and proposed fragmentation pathways.

Compound	Transition	Proposed fragmentation
Bendamustine	358 → 228	
M3	374 → 338	
M4	344 → 186	
BM-IS	372 → 354	
HP2	322 → 304	
α-Dansyl-L-arginine	407 → 170	